Shili Xu

Assistant Professor, Director of Crump Preclinical Imaging Technology Center

UCLA
Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Shili Xu is an Assistant Professor and the Director of the Crump Preclinical Imaging Technology Center at UCLA, USA. His research focuses on advanced imaging techniques and cancer biology, with recent publications addressing topics such as three-dimensional printing of the human pericardium, gene therapy imaging, and the metabolic adaptations of cancer cells during therapy. He is actively involved in developing innovative methods for tracking tumor progression and characterizing cancer metabolism.

Articles (13)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Background Resistance to existing therapies is a significant challenge in improving outcomes for glioblastoma (GBM) patients. Metabolic plasticity has emerged as an important contributor to therapy resistance, including radiation therapy (RT). Here, we investigated how GBM cells reprogram their glucose metabolism in response to RT to promote radiation resistance. Methods Effects of radiation on glucose metabolism of human GBM specimens were examined in vitro and in vivo with the use of metabolic and enzymatic assays, targeted metabolomics, and FDG-PET. Radiosensitization potential of interfering with M2 isoform of pyruvate kinase (PKM2) activity was tested via gliomasphere formation assays and in vivo human GBM models. Results Here, we show that RT induces increased glucose utilization by GBM cells, and this is accompanied with translocation of GLUT3 transporters to the cell membrane. Irradiated GBM cells route glucose carbons through the pentose phosphate pathway (PPP) to harness the antioxidant power of the PPP and support survival after radiation. This response is regulated in part by the PKM2. Activators of PKM2 can antagonize the radiation-induced rewiring of glucose metabolism and radiosensitize GBM cells in vitro and in vivo. Conclusions These findings open the possibility that interventions designed to target cancer-specific regulators of metabolic plasticity, such as PKM2, rather than specific metabolic pathways, have the potential to improve the radiotherapeutic outcomes in GBM patients.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (5)

Erina Vlashi

University of California

UNITED STATES
View details

René Packard

University of California, Los Angeles

UNITED STATES
View details

Evan Abt

Adjunct Assistant Professor

UCLA

UNITED STATES
View details

Alex Wong

Assistant Professor

Yale University

UNITED STATES
View details

Steve Cole

UCLA School of Medicine

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.